While Sanofi hasn’t been at the forefront of global COVID-19 vaccination efforts, the company still has big growth expectations in the vaccines field. Already the world’s top flu shot player, Sanofi sees mRNA, pneumococcal vaccines and respiratory syncytial virus (RSV) as three areas of opportunity going forward.
By expanding the reach of its existing offerings, launching new vaccines and advancing pipeline shots, Sanofi expects to more than double its vaccine sales by the end of the decade from a starting point of 2018’s 5.11 billion euros, execs said during a vaccines investor day Wednesday.
Sanofi expects the global flu vaccine market to more than double to 15 billion euros by 2030, with its own shots serving as a “key driver of that market expansion,” Sanofi’s head of vaccines, Thomas Triomphe, said during the event.
